Diabetes mellitus type MODY 1
DOI:
https://doi.org/10.32818/reccmi.a3n1a13Keywords:
diabetes mellitus, MODY, maturity onset diabetes mellitus.Abstract
We show a 24-year-old Arab patient who was admitted to severe pneumococcal pneumonia. During the ad- mission she was diagnosed with type-2 diabetes, overweight and hypertriglyceridemia. The autoimmunity was negative and the C-peptide was normal as well. After starting treatment with metformin and fibrates the metabolic control improved, nevertheless she eventually required the start of a second antidiabetic drug with iSGLT-2. Due to the fact that there was not entirely favorable evolution and the lack of obesity, we decided to rule out a MODY. Genetic tests confirmed a mutation in the HNF4A gene. She was diagnosed with MODY-1.
Downloads
Metrics
References
Mohan V, Radha V, Nguyen T, et al. Comprehensive genomic analysis identifies pathogenic variants in maturity onset diabetes of the Young (MODY) patients in South India. BMC Medical Genetics. 2018; 19: 22.
Naylor RN, John PM, Winn AN, et al. Costeffectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care. 2014; 37: 202–209.
Shields B, Colclough K. Towards a systematic nationwide screening strategy for MODY. Diabetologia. 2017; 60: 609-612.
Hattersley A, Patel K. Precision diabetes: learning from monogenic diabetes. Diabetologia. 2017; 60: 769-777.
Standards of medical care in diabetes-2018. Diabetes Care. 2018 Jan; 41 Suppl 1.
Brunerova L, Rahelic D, Ceriello A, et al. Use of oral antidiabetic drugs in the treatment of madurity onset diabetes of the Young: A mini review. Diabe- tes Metab Res Rev. 2018; 34: e2940.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Ana Isabel Ostos-Ruiz, María Soto-Martín, María Pérez-Aguilera, Elena Concejo-Martínez, Francisco Javier Carrasco-Sánchez
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
